Artemis Investment Management LLP lowered its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 21.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,302 shares of the medical research company’s stock after selling 9,063 shares during the quarter. Artemis Investment Management LLP’s holdings in Edwards Lifesciences were worth $7,093,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $26,000. Evolution Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $29,000. M&R Capital Management Inc. acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $29,000. Next Capital Management LLC boosted its position in Edwards Lifesciences by 297.7% during the 2nd quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock worth $32,000 after acquiring an additional 128 shares during the last quarter. Finally, Tarbox Family Office Inc. boosted its position in Edwards Lifesciences by 48.7% during the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after acquiring an additional 58 shares during the last quarter. 81.53% of the stock is owned by hedge funds and other institutional investors.
In related news, Director William J. Phd Link sold 10,214 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $221.86, for a total value of $2,266,078.04. Following the sale, the director now owns 16,817 shares in the company, valued at approximately $3,731,019.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Robert W.A. Sellers sold 17,417 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $211.57, for a total value of $3,684,914.69. Following the completion of the sale, the vice president now owns 23,655 shares in the company, valued at approximately $5,004,688.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 155,822 shares of company stock worth $33,641,784. 1.63% of the stock is owned by company insiders.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the business earned $1.24 EPS. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. As a group, sell-side analysts predict that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.
A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $190.00 to $225.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Wells Fargo & Co increased their price objective on Edwards Lifesciences from $220.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, September 6th. ValuEngine downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a report on Thursday, July 25th. Finally, Credit Suisse Group increased their price objective on Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $213.33.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: Initial Public Offering (IPO)
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.